Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aCoV2 Vaccine for COVID-19
NCT04806529Phase 3Withdrawn
- Sponsor
- CSL Seqirus
- Start
- Dec 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Protein Vaccines
01
Overview
A Phase 3 trial of UQ-CSL V451 in coronavirus disease 2019 (COVID-19), sponsored by CSL Seqirus. Planned start Dec 2020; status: withdrawn.
02
Drugs
UQ-CSL V451
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04806529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806529.